The BBC’s latest piece on Denmark’s remarkable progress in cancer care is a powerful reminder of what can happen when vision, investment, and innovation align.

Two decades ago, Denmark’s cancer outcomes were described as a “disaster.” 

Survival rates lagged far behind peer nations, patients sought experimental treatments abroad, and politicians were scrambling for answers. 

Today, the country is a global benchmark in oncology, with rectal cancer survival rates climbing from 48% in the late 1990s to nearly 70% by 2014 — one of the highest in the world.

The turnaround came through a bold plan: investing heavily in diagnostic equipment, enforcing strict treatment timelines, enabling chemotherapy at home, and even rethinking the atmosphere of hospitals. 

Denmark proved that systemic change, patient-focused care, and long-term political consensus can deliver extraordinary results.

Why this matters for 2cureX

For us at Koodos, the article reads like a blueprint for why companies such as 2cureX are so important to the future of cancer treatment.

• Faster diagnosis and treatment decisions: Denmark prioritised speed — and 2cureX’s IndiTreat® test is built for exactly that, providing oncologists with actionable data in weeks, not months.
  
  

• Personalisation at scale: The shift away from “one-size-fits-all” cancer therapy is clear. IndiTreat® is the world’s only regulatory-approved functional precision oncology test for colorectal cancer, ensuring treatment is matched to each patient’s unique biology.
  
  

• Innovation backed by validation: As the BBC article makes clear, bold investments in technology drive progress. 2cureX combines regulatory approval with scientific innovation, and with its upcoming merger with PreComb Therapeutics, that potential expands significantly.

A sector set to accelerate

The merger of 2cureX and PreComb represents the best of both worlds: proven regulatory validation paired with a cutting-edge platform for wider adoption. 

Together, they’re positioned to set the pace in the move towards personalised oncology.

For investors, healthcare leaders, and patients alike, this is a moment of third-party validation. 

The BBC’s coverage underscores the unmet need, the scale of the opportunity, and the urgency of accelerating innovation in cancer care.

At Koodos, we back founders and companies willing to take on industries that matter most. Precision oncology is one of them — and with 2cureX and PreComb, the future looks promising.

👉 Read the full BBC article here

Learn more about Koodos portfolio opportunities here.